search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
www.chemicalsknowledgehub.com


Lonza and Pionyr Immunotherapeutics in oncology product development agreement


B


asel, Switzerland, 29 March 2021 – Lonza and Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body’s anti- tumour immunity, have entered into a collaboration in which Lonza will manufacture Pionyr’s monoclonal antibody candidate intended for oncology indications. Lonza will provide a gene to IND programme tailored to suit the specific requirements of Pionyr’s products that will include cell line development, process development, supply chain simplification, and de-risking, as well as drug substance (DS) manufacturing


development and testing. The cell line development to drug product programme will begin in Q2 2021. The cGMP batches of drug substance and drug product are expected to be completed in early 2022.


The collaboration will initially


Lonza will manufacture Pionyr Immunotherapeutics’ PY265 oncology candidate drug substance at its Visp facility (pictured), with drug product manufacturing taking place at the company’s Stein facility. The two facilities are located in Switzerland. (Photo: ©Lonza Ltd)


at Lonza’s Visp site, and drug product manufacturing at its Stein


SOCMA to hold Policy Webinar Series in April


In anticipation of new policy and regulations coming under the Biden Administration, the Society of Chemical Manufacturers & Affiliates (SOCMA) is hosting its Policy Webinar Series throughout April to focus on key topics it says are crucial to its membership and the value chain.


“With the new administration’s


initiatives under way, there are numerous regulatory changes and potential effects to the very framework of the speciality and fine chemical industry,” said Robert Helminiak, Vice President, Legal and Government Relations. “SOCMA’s Policy Webinar Series will deliver critical intelligence and background information on legislation, trade impacts, compliance challenges, worker health and safety requirements and ongoing regulatory activities that our member companies can utilize to ensure optimal business performance within the Biden Administration. These foundational issues significantly impact the specialities industry, and our members rely on SOCMA to


Issue 2 • March/April 2021


obtain essential guidance necessary to the success of their operations.” Each webinar includes subject-


matter experts from SOCMA member companies, industry partners and key federal agencies. Session dates, topics and speakers are as follows: Thursday, April 1 – COVID-19 Employer Vaccination Policy & Insurance Considerations | Expert panelists are Megan Glowacki, Partner, Thompson Hine, and Scott A. Watson, Vice President, McGriff Insurance. Thursday, April 8 – OSHA’s New Hazard Communication Requirements|Expert panelist is Amy Wachs, Partner, Husch Blackwell. Thursday, April 15 – Trade Impacts on the Chemical Supply Chain – MTB, China 301 Tariffs, GSP, and More


Thursday, April 22 – A Closer Look at the Biden EPA and its Impact on the Specialty Chemical Industry For further information visit www. socma.com or contact SOCMA’s Government Relations team at government.relations@socma.org


facility to help Pionyr advance its programmes into clinical


focus on Pionyr’s third programme, named PY265, which is directed against an undisclosed target. Similar to Pionyr’s PY314 and PY159 programmes targeting TREM2 and TREM1, respectively, this third programme is expected to be first-in-class and will have a distinct mechanism of action from other myeloid-directed therapeutics currently in development.


People on the Move


Astrea Bioseparations, a gamma Biosciences company, has made two senior management appointments: Gabe Longoria has joined Astrea as Chief Commercial Officer effective April 5. Dr Marc Hummersone joined Astrea as Senior Director of Research and Development in January of this year. Longoria has more than 25 years of commercial experience in life sciences and biotherapeutics with a track record of driving commercial growth. He formerly served as Global Head of Commercial at Horizon Discovery, leading customer facing operations and strategy. Prior to Horizon, he held several senior roles focused on commercial acceleration and sales success at Danaher Corporation companies Molecular Devices, Leica Microsystems and Genetix, as well as Ventana Medical Systems, a member of the


Roche Group. Similarly, Dr Hummerstone has more than two decades of expertise in the life sciences sector, having led technology innovation teams in both large and small organizations, with extensive experience in drug discovery and development as well as biopharmaceutical manufacturing. He holds a PhD in Chemistry and joins Astrea from Cytiva (formerly GE Healthcare). He was previously Chief Scientific Officer of Puridify (purchased by GE Healthcare).


Gamma Biosciences acquired Astrea in late 2019 and has invested substantially to grow the business in its core and adjacent markets, both organically and inorganically. In 2020, Gamma added Essential Life Solutions and Nanopareil to its bioseparations offering and continues to look for opportunities to expand its growing presence in downstream processing.


13


Industry News


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64